Your browser doesn't support javascript.
loading
Target deconvolution from phenotype-based drug discovery by using chemical proteomics approaches.
Kubota, Kazuishi; Funabashi, Masanori; Ogura, Yuji.
Afiliação
  • Kubota K; Research Management Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan. Electronic address: kubota.kazuishi.ci@rdn.daiichisankyo.co.jp.
  • Funabashi M; Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan. Electronic address: funabashi.masanori.ea@rdn.daiichisankyo.co.jp.
  • Ogura Y; Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan. Electronic address: ogura.yuji.hh@rdn.daiichisankyo.co.jp.
Biochim Biophys Acta Proteins Proteom ; 1867(1): 22-27, 2019 01.
Article em En | MEDLINE | ID: mdl-30392561
ABSTRACT
Phenotype-based drug discovery is a key strategy for small molecule drug screening, and the molecular target identification of small molecules, termed "target deconvolution," is critical albeit challenging. In this review, we classify approaches for target deconvolution, including both direct and indirect approaches, summarize their underlying principles, and provide examples of current chemical proteomics strategies including affinity purification using compound-immobilized beads, photoaffinity labeling (PAL), cellular thermal shift assay (CETSA), and activity-based protein profiling (ABPP). Because there is no single best target deconvolution strategy, it is important to carefully select a strategy on the basis of the test compound characteristics.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteômica / Avaliação Pré-Clínica de Medicamentos / Descoberta de Drogas Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteômica / Avaliação Pré-Clínica de Medicamentos / Descoberta de Drogas Idioma: En Ano de publicação: 2019 Tipo de documento: Article